SUTRO BIOPHARMA, INC. STRO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-22.06
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $102.5M | -$191.1M | — | — | -$132.5M |
| 2024 | $62.0M | -$227.5M | — | — | $44.6M |
| 2023 | $153.7M | -$106.8M | — | — | $149.6M |
| 2022 | $67.8M | -$119.2M | — | — | $217.0M |
| 2021 | $61.9M | -$105.5M | — | — | $252.6M |
| 2020 | $42.7M | -$32.1M | — | — | $332.0M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -22.06 (distress)
- Working capital / assets 0.436
- Retained earnings / assets -5.626
- EBIT / assets -0.911
- Equity / liabilities -0.432
Source: SEC EDGAR filings · CIK 0001382101 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.